Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials | The Journal of Headache and Pain | Full Text

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials | The Journal of Headache and Pain | Full Text

• 
• 
• The Journal of Headache and Pain is affiliated with the European Headache Federation and Lifting the Burden.

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

Galcanezumab is a novel monoclonal antibody that target to calcitonin gene-related peptide (CGRP). It has been tested for the preventive treatment of migraine and episodic cluster headache by multiple randomiz...

Authors:Yanbo Yang, Zilan Wang, Bixi Gao, He Xuan, Yun Zhu, Zhouqing Chen and Zhong Wang

Citation:The Journal of Headache and Pain 2020 21:14

Content type:Research article

Published on: 11 February 2020

• ViewFull Text
 
• ViewPDF